Tier A — large human RCTs, regulatory approval

Semaglutide & Tirzepatide

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP + GLP-1 receptor agonist.

Conceptual chain illustration for Semaglutide & Tirzepatide — for representation purposes only. Not the compound's verified molecular structure.

Evidence

Large, well-run human RCT programmes. Regulatory approval in major markets for type 2 diabetes and, in specific formulations, weight management.

Mechanism

Glucose-dependent insulin secretion, slowed gastric emptying, central appetite signalling.

This page is intentionally mechanism-only. These compounds sit under scheduled-condition advertising restrictions in several jurisdictions, India included — nothing here should be read as advertising toward weight loss or diabetes. If you're a clinician or researcher with questions, reach out directly.

Also worth knowing

These molecules are under active patent in most markets. Unlicensed copies carry intellectual-property exposure independent of any regulatory question.

Have a question?